146 related articles for article (PubMed ID: 32729618)
1. PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer.
Zhang M; Zhang J
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32729618
[TBL] [Abstract][Full Text] [Related]
2. LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma.
Yu G; Mu H; Fang F; Zhou H; Li H; Wu Q; Xiong Q; Cui Y
Medicine (Baltimore); 2022 Jul; 101(26):e29763. PubMed ID: 35777027
[TBL] [Abstract][Full Text] [Related]
3. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
4. An miRNA signature associated with tumor mutation burden in endometrial cancer.
Zhou H; Chen L; Qin M; Lei Y; Li T; Li H; Cheng X
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33141168
[TBL] [Abstract][Full Text] [Related]
5. ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration.
Wang J; Zhang X; Li J; Ma X; Feng F; Liu L; Wu J; Sun C
Aging (Albany NY); 2020 Nov; 13(1):351-363. PubMed ID: 33234738
[TBL] [Abstract][Full Text] [Related]
6. Mutations in lysine methyltransferase 2C and PEG3 are associated with tumor mutation burden, prognosis, and antitumor immunity in pancreatic adenocarcinoma patients.
Huang Y; Liu J; Zhu X
Digit Health; 2022; 8():20552076221133699. PubMed ID: 36312851
[TBL] [Abstract][Full Text] [Related]
7. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.
Li X; Pasche B; Zhang W; Chen K
JAMA Oncol; 2018 Dec; 4(12):1691-1698. PubMed ID: 30098163
[TBL] [Abstract][Full Text] [Related]
8. MDN1 Mutation Is Associated With High Tumor Mutation Burden and Unfavorable Prognosis in Breast Cancer.
Hao S; Huang M; Xu X; Wang X; Huo L; Wang L; Gu J
Front Genet; 2022; 13():857836. PubMed ID: 35386280
[No Abstract] [Full Text] [Related]
9. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
10. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
[TBL] [Abstract][Full Text] [Related]
11. GATA3 somatic mutations are associated with clinicopathological features and expression profile in TCGA breast cancer patients.
Afzaljavan F; Sadr AS; Savas S; Pasdar A
Sci Rep; 2021 Jan; 11(1):1679. PubMed ID: 33462316
[TBL] [Abstract][Full Text] [Related]
12. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.
Chappuis PO; Donato E; Goffin JR; Wong N; Bégin LR; Kapusta LR; Brunet JS; Porter P; Foulkes WD
Ann Oncol; 2005 May; 16(5):735-42. PubMed ID: 15802279
[TBL] [Abstract][Full Text] [Related]
13. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
[TBL] [Abstract][Full Text] [Related]
14. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
15. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
[TBL] [Abstract][Full Text] [Related]
16. BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.
Wunderle M; Gass P; Häberle L; Flesch VM; Rauh C; Bani MR; Hack CC; Schrauder MG; Jud SM; Emons J; Erber R; Ekici AB; Hoyer J; Vasileiou G; Kraus C; Reis A; Hartmann A; Lux MP; Beckmann MW; Fasching PA; Hein A
Breast Cancer Res Treat; 2018 Aug; 171(1):85-94. PubMed ID: 29725888
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
18. KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
Liu X; Qiu R; Xu M; Meng M; Zhao S; Ji J; Yang Y
Breast Cancer Res Treat; 2021 Sep; 189(2):347-361. PubMed ID: 34240274
[TBL] [Abstract][Full Text] [Related]
19. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
[TBL] [Abstract][Full Text] [Related]
20. Are we ready to use TMB in breast cancer clinical practice?
Ravaioli S; Limarzi F; Tumedei MM; Palleschi M; Maltoni R; Bravaccini S
Cancer Immunol Immunother; 2020 Oct; 69(10):1943-1945. PubMed ID: 32725361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
